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Novelty Statement 
This review is the first to systematically evaluate the evidence for a link between HbA1c and 
cancer risk. It outlines the relationships between HbA1c and the incidence and mortality of all 
and site-specific cancers. Furthering our understanding of the relationship between HbA1c 
and cancer is of great clinical and academic interest.  This review goes some way to outlining 
these associations and highlighting areas where more research is needed. 
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Abstract 
Aims Cancer is a major public health problem accounting for 8.2 million deaths worldwide in 
2012. Glycated Haemoglobin (HbA1c) is associated with the risk of developing certain 
cancers, though the existing evidence is conflicting. The aim of this systematic review is to 
identify the relationship between HbA1c and cancers in people with or without diabetes.  
Methods Embase, Medline, Cinahl and Cochrane Library were searched. Eligible articles 
included randomised-controlled trials, cohort studies, case-control studies, systematic reviews 
and meta-analyses. Participants of either sex, with or without type 1 or 2 diabetes, were 
included. The studies were assessed using the Scottish Intercollegiate Guidelines Network 
(SIGN) criteria by two independent assessors. No meta-analysis was performed due to 
heterogeneity of results. 
Results Nineteen studies from 1006 met the inclusion criteria. Fourteen were cohort studies 
and five nested case control studies. Eight studies investigated outcomes for all cancer sites. 
Four of these studies reported that higher HbA1c levels were associated with increased 
incidence and/or mortality risk for all cancers. One study observed a U-shape relationship 
between HbA1c and cancer incidence and mortality. Increasing HbA1c levels were associated 
with increased risk of developing colorectal, pancreatic, respiratory and female genital tract 
cancers. No increased risk was observed for breast cancer, gastrointestinal or urological 
malignancies.  
Conclusion HbA1c appears to be associated with cancer incidence and/or cancer mortality. 
However, further studies are needed to fully understand the complex relationship between 
HbA1c and cancer. 
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Introduction 
Cancer and diabetes represent two leading causes of morbidity and mortality globally and 
their increasing prevalence represents a significant public health burden. Cancer incidence in 
the UK has increased by more than a third since the 1970s [1], resulting in the need for more 
research to identify and enable modification of risk factors for cancer development. Similarly, 
diabetes incidence in the UK is increasing with 3.8 million people predicted to be affected by 
2020 [2]. Glycated haemoglobin (HbA1c) is the mainstay for monitoring glycaemic control in 
diabetes and more recently has been advocated for the diagnosis of Type 2 diabetes at a level 
of 48mmol/mol (6.5%) [3].  
 
Various studies have reported an association between diabetes or the metabolic syndrome 
with increased cancer risk [4,5]. In a recent study [6], which evaluated 27 meta-analyses 
investigating type 2 diabetes and the risk of developing or dying from cancer, associations 
between type 2 diabetes and breast, cholangiocarcinoma, colorectal and endometrial cancers 
were found. It is unclear whether hyperglycaemia per se is associated with increased cancer 
risk in the absence of diabetes. The exact mechanisms remain unknown but a role for 
hyperinsulinaemia [7], inflammation and the effects of insulin-like growth factor 1 (IGF-1) 
has been proposed. HbA1c has also been shown to be an important marker for the metabolic 
processes that determine insulin [8] and IGF-1 levels [9, 10] and thus may be linked to the 
disease process in people with type 2 diabetes, highlighted above.  
 
Previous studies have reported an association between increased HbA1c and increased risk of 
cancer, but these studies have been limited to people with diabetes or used HbA1c values as 
discrete, rather than continuous variables. Further developing our understanding of the 
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relationship between HbA1c and cancer aetiology, in specific cancers, is of clinical 
importance. We aim to assess the relationship between HbA1c and all and site specific cancers 
in people with or without diabetes.   
 
Materials and methods 
Searches 
Medline, Embase, Cochrane and Cinahl were searched for articles evaluating the relationship 
between cancer risk and HbA1c, published between January 1990-October 2014 (See Fig.1). 
The search was limited to human studies written in English. The reference lists of included 
articles were reviewed. 
 
Study criteria 
Articles included met the following criteria: (i) the association of HbA1c and cancer risk in 
people with or without diabetes was evaluated, and (ii) the diabetes diagnostic criteria were 
clearly defined. Randomised-controlled trials, case-control studies, cohort studies and meta-
analyses were included in the search. Children (<18 years) and pregnant women were 
excluded. Case reports, case series studies, and other studies that were not published as full 
articles were excluded. 
 
Study selection 
Titles, abstracts and full texts of articles were reviewed by two independent assessors (CH 
and AR). The quality of the included studies was assessed using SIGN criteria. Methodology 
checklists for both cohort and case control studies were reviewed, and relevant aspects from 
each were employed to critically appraise and grade the evidence of included studies. Quality 
assessment was not used as an exclusion criterion.  
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Additional analyses 
No meta-analyses or other statistical analyses were conducted due to the variation within 
study methodology and heterogeneity of results. Particularly, the categorisation of HbA1c 
levels varied widely between studies making direct comparison difficult. 
 
Results 
The searches (Fig. 1) identified 1006 articles. The main reasons for exclusion on reading the 
full text were an inadequate definition of diabetes or the article did not assess HbA1c and 
cancer risk. Nineteen met the inclusion criteria and were evaluated and quality assessed. 
 
Study characteristics 
Of the 19 articles, 14 were cohort studies and 5 were nested case control studies (Table 1). 
There was considerable variation within study designs, particularly concerning the 
stratification of HbA1c with both percentage (%) and SI units (mmol/mol) used as units of 
measurement. Data were included from a range of people with and without diabetes. Most 
studies were conducted prior to the updated American Diabetes Association (ADA) and 
World Health Organization (WHO) guidelines recommending the measurement of HbA1c for 
the diagnosis of diabetes. Therefore, diagnosis of diabetes was based primarily on self-report, 
fasting plasma glucose concentration and oral glucose tolerance tests. Participants without 
diabetes were considered those without a formal diagnosis prior to the study commencing.  
 
All cancers 
Eight studies focused on the relationship between HbA1c and all types of cancer [10-17], 
summarised in Table 2. All studies were adjusted for age, sex and smoking status. 
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Three studies investigated HbA1c and cancer in people without diabetes. A total of 12,792 
individuals were included in a study by Joshu et al [10]. The most common incident cancers 
among women were post-menopausal breast (31%), lung (10%) and colorectal cancer (10%). 
The study additionally adjusted for body mass index (BMI), ethnicity, systolic blood pressure 
and education level. Women without diabetes with an HbA1c >39mmol/mol (>5.7%) had a 
24% higher cancer incidence rate compared to those with HbA1c 31-38mmol/mol (5-5.6%) 
but a 27% increase in cancer incidence rate was also noted in HbA1c levels below 
31mmol/mol (5%), indicating a U-shape relationship between HbA1c and all types of cancer 
incidence. In contrast, no positive relationship was seen between HbA1c levels and cancer risk 
in men. Prostate made up 39% of the incident cancer cases, with 15% lung and 10% 
colorectal cancer. The known inverse relationship between prostate cancer and diabetes was 
taken into account and all cancer and all cancer minus prostate cancer were compared.  
 
In Jonasson’s [14] study of 25,476 people with type 2 diabetes no associations between 
HbA1c and risk for all cancers or site specific cancers were observed.  Insulin treatment, 
duration of diabetes and BMI were adjusted for. Twenty-four percent of cancer cases were 
made of up gastrointestinal cancer, 22% of prostate, 9% breast and 2% lung cancer. 
 
A study by Travier [15] comprised 46,575 participants. Oral and digestive system cancers 
made up 18% of new cancer cases, respiratory cancers 12% and colorectal cancer 6%. While, 
female breast cancer accounted for 34% of new cancer cases found in women. A significantly 
increased hazard ratio for risk of all cancers was found in those with HbA1c 42-52mmol/mol 
(6%-6.9%) (HR 1.40, CI 95%: 1.11-1.76), compared to those with HbA1c <42mmol/mol 
(<6%). A smaller non-significant 9% increase was observed in levels >53mmol/mol (>7%) 
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(HR 1.09, CI 95%:0.80-1.48). This study had a short median follow up of 4.4 years and 
therefore potentially undiagnosed cancers were included. It also lacked any anthropometric 
data so confounders such as BMI were not accounted for. 
 
Six studies investigated the relationship between HbA1c and cancer mortality. The study by 
Joshu et al [10] investigated the association between all and site specific cancer mortality 
rates and HbA1c. Lung cancer was the most commonly reported cause of cancer death in both 
men and women (35% and 28%), with colorectal cancer conveying an 9% mortality rate in 
men and 8% in women. A similar U-shape relationship was observed, where women without 
diabetes with an HbA1c <31mmol/mol (<5%) were found to have an 82% increase in cancer 
mortality and rates also increased with incremental increases in HbA1c above 39mmol/mol 
(>5.7%). Cancer mortality in men was not affected by HbA1c level. 
 
Nakanishi et al [11] studied the effects of HbA1c levels on cancer specific mortality in a 
Japanese cohort. After adjustment for BMI, blood pressure, total cholesterol, smoking and 
alcohol intake, HbA1c >48mmol/mol (>6.5%) significantly increased the hazard ratios for 
mortality from malignant neoplasms (HR 1.62; CI 95% 1.00-2.61, p=0.0015). The study 
provides no breakdown of the type of malignant neoplasm which limits comparison to the 
other studies. 
 
Parekh et al [12] evaluated the impact of markers of glucose and insulin metabolism on site 
specific and overall cancer mortality in 15,594 people. Lung cancer made up the majority of 
cancer deaths (9%), followed by colorectal (2.2%). Breast cancer accounted for 1.5% of 
cancer mortality as did prostate cancer. There was a borderline significant 22% increased 
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hazard ratio for death from cancer for each 2mmol/mol (2%) increment in HbA1c (HR: 1.22; 
95% CI: 0.96-1.55) after adjusting for age, sex, physical activity, smoking history and BMI.   
Saydah et al [13] investigated the relationship between HbA1c and overall cancer mortality 
rates in 19,025 people of mixed diabetic status. HbA1c levels >64mmol/mol (>8%) were 
associated with a more than twofold increase in relative risk of cancer mortality compared to 
those with HbA1c levels <42mmol/mol (<6%). Overall, they concluded that increasing levels 
of HbA1c were associated with increased cancer mortality, however, no breakdown of the 
specific types of cancer was provided.  
 
Silbernagel et al [16] reported that HbA1c significantly predicts overall cancer mortality. 
Lung cancer was analysed separately but other specific cancers were not analysed due to 
small numbers. BMI and ethnicity were also adjusted for. Participants with HbA1c 48-
57mmol/mol (6.5-7.4%) had a significantly higher hazard ratio for cancer mortality than 
those with HbA1c <31mmol/mol (<5%) [p=0.032]. Additional confounders such as 
hypertension and cholesterol levels were considered. No details on the specific types of 
cancer were included. A major limitation of this study was the selection of a non-
representative sample as patients were recruited post coronary angiography and only 
Caucasians were included. 
 
Hsu et al [17] examined the relationship between cancer mortality and glycaemic biomarkers 
of type 2 diabetes. HbA1c was not found to be related to all-cause cancer mortality among 
2,509 people without diabetes.  
 
The above studies combine cancer incidence and mortality. Three studies [10, 14, 15] 
investigated HbA1c level and the risk of developing all cancers. Of these, a positive 
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association was observed in two studies [10, 15]. Positive relationships between increasing 
HbA1c and cancer mortality were also noted [10, 11, 13, 16]. These relationships were noted 
at the extremes of HbA1c level and seem to affect women more so than men. 
 
Breast Cancer 
Four cohort studies investigated the association between HbA1c and breast cancer [10, 14, 15, 
18]. All were large cohorts ranging from 12,792 to 46,575 participants. Joshu et al [10] found 
that women with HbA1c of ≥39mmol/mol (≥5.7%) or <31mmol/mol (<5%) did not have 
significantly higher incidence rates of post-menopausal breast cancer compared to the 
reference (31-38mmol/mol, 5-5.6%). When compared to women without diabetes, women 
with diabetes had a non-significant increase in HR for post-menopausal breast cancer [HR 
1.30, 95% CI: 0.92-1.83] and mortality [HR 2.34, 95% CI: 0.97-5.62]. 
 
Jonasson’s study in type 2 diabetes [14], did not expose a relationship between HbA1c and 
breast cancer. No significant differences in risk were found between HbA1c levels higher or 
lower than the cohort median (52mmol/mol, 6.9%). Lin et al [18] investigated whether HbA1c 
levels could predict breast cancer risk in 27,110 women without diabetes. Overall, they 
concluded that high HbA1c levels had no effect on breast cancer risk. A weakly inverse 
relationship was observed among post-menopausal women who had never used hormone 
replacement therapy (p=0.06). Within another cohort without diabetes, Travier et al [15] did 
not observe an increased risk among all women, or following stratification by menopausal 
status.  
 
None of the four studies found any significant association between HbA1c and the risk of 
developing breast cancer. The studies were of considerable sample size and good 
10 
 
methodology.  Although, only the studies by Lin and Joshu adjusted for post-menopausal 
hormone use. 
 
Colorectal Cancer 
Five cohort studies and three nested case control studies evaluated HbA1c in relation to 
colorectal cancer [10, 15, 19-24]. In a cross sectional study of 2,776 people with and without 
diabetes, Hsu et al [19] investigated the association between measures of glycaemic index 
and colorectal neoplasia, odds ratios were used to measure the associations. Neoplasia 
included adenomas and cancerous lesions. For analysis the authors divided neoplasia into 
‘any neoplasia’ and ‘high risk neoplasia’. It should be noted that only 2 cases had colorectal 
cancer. HbA1c was found to be an independent risk factor (p<0.001) for colorectal neoplasia 
for the whole cohort after multivariate analysis. HbA1c was superior to fasting plasma glucose 
as a risk indicator which led the authors to speculate about the use of HbA1c in colorectal 
cancer screening programmes. 
 
A large study by Joshu et al [10] identified a non-significant increase in incidence rate of 
colorectal cancer within men [HR 1.52, 95% CI: 0.88-2.60] and women [HR 1.55, 95% CI: 
0.88-2.75] with diabetes, compared to those without diabetes (reference; 31-38mmol/mol, 5-
5.6%). A significant increase in colorectal cancer [HR 1.84, 95% CI: 1.07-3.18] was also 
observed for men without diabetes, with HbA1c <31mmol/mol (<5%).  
 
Khaw et al [20] studied 9,605 men and women with and without diabetes. Mean HbA1c 
concentration was significantly higher within incident colorectal cancer cases [p=0.005]. 
Those with known or undiagnosed diabetes (HbA1c ≥53mmol/mol, ≥7%, but no reported 
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diabetes) had a 4-fold increase in incident colorectal cancer rate compared to persons with 
HbA1c <31mmol/mol (<5%) [p for trend <0.001]. 
 
Rinaldi et al [21] enrolled 1,026 colorectal cancer cases, with and without diabetes, and an 
equal number of matched controls. Increasing HbA1c percentages were associated with 
increased odds ratios for colorectal cancer incidence [OR 1.10, 95% CI: 1.01-1.19 per 10% 
rise in HbA1c]. This relationship was also true of women separately [OR 1.16, 95% CI: 1.01-
1.32]. No such relationship was observed in men. The methodological quality of these studies 
was good, though minimisation of confounding factors was not thoroughly addressed. Each 
failed to account for at least one of the following; BMI, race/ethnicity, alcohol intake and 
smoking. 
 
Three studies focused on cohorts without diabetes only. Saydah et al [22] found that higher 
HbA1c levels >40mmol/mol (>5.8%) were associated with increased risk of colorectal cancer 
(OR, 1.57; 95% CI, 0.94–2.60; p for trend 0.02) compared to 346 controls matched for age, 
race, and sex. Risk was 57% higher in the top quartile of HbA1c compared to the bottom 
quartile, however this did not reach significance. 
 
Travier et al [15] identified no risk increases for colorectal cancer among people without 
diabetes. Likewise, Platz et al [23] did not find HbA1c to significantly differ between 280 
women without diabetes and colorectal cancer and 357 matched controls without colorectal 
cancer. Additionally among 27,110 women without diabetes [24], HbA1c levels were not 
correlated to cancers of the proximal colon, distal colon or rectum. The methodological 
quality of the previous two studies, including assessment of confounding factors, was very 
good.  
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Five out of eight studies identified an increased risk of colorectal cancer with higher HbA1c 
levels. One study also suggested that very low HbA1c levels (<31mmol/mol, <5%) may 
increase incidence of colorectal cancer. Two of the studies which established a null 
relationship were of considerably larger sample sizes and subsequently have greater statistical 
power. However, on balance, the presence of some association cannot be excluded. 
 
Gastric Cancer 
Three population-based cohort studies investigated the relationship between HbA1c and 
gastric cancer risk [14, 15, 25]. All three studies adjusted for age, sex and smoking status. 
Ikeda et al [25] investigated the impact of HbA1c level on gastric cancer occurrence and the 
interaction with Helicobacter pylori (H.pylori) in people with and without diabetes. They 
concluded that HbA1c levels 42-52mmol/mol (6-6.9%) (p=0.003) significantly increased 
hazard ratios for the risk of gastric cancer, this remained significant after multivariate 
adjustment for other risk factors including H.pylori seropositivity, BMI and alcohol intake. 
The co-existence of elevated HbA1c ≥42mmol/mol (≥6%) and H.pylori infection similarly 
resulted in increased risk (HR, 4.03; 95% CI: 1.89-8.58; p <0.001). The methodology of this 
study thoroughly accounted for confounding factors with a moderate sample size of 2603 
patients. The two remaining large studies by Travier et al [15] and Jonasson et al [14] 
(46,575 and 25,476 respectively), found no correlation between HbA1c levels and 
gastric/gastrointestinal cancer risk in those without diabetes or participants with type 2 
diabetes. Neither study, considered H.pylori status as a confounder.   
 
Based on the current available evidence, it is not possible to state whether HbA1c effects 
gastric cancer risk. 
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Pancreatic cancer 
Three studies investigated the relationship between HbA1c and pancreatic cancer [26-28]. All 
studies comprised male and female participants. All three adjusted for age, sex and smoking 
status. Two studies [26, 27] included people with and without diabetes. Grote et al [26] 
investigated the role of HbA1c and C-peptide levels in the development of pancreatic cancer. 
A total of 466 participants with pancreatic cancer were matched with an equal number of 
controls, with and without diabetes. A statistically significant increase in odds ratio for 
pancreatic cancer was observed with increasing HbA1c levels within the whole population [p 
for trend= 0.002], and within those without diabetes [p for trend= 0.02], even after 
adjustment for BMI, diabetes status and smoking status. The overall methodology of this 
prospective study was good however, confounding factors such as alcohol intake and 
ethnicity were not considered. Also, risk was not given per unit HbA1c which would have 
enabled further conclusions. 
 
Wolpin et al [28] evaluated HbA1c within a population of 449 participants and 982 matched 
controls, without diabetes. Again, increasing HbA1c levels were associated with a significant 
increase in odds ratios [p for trend= 0.04] for pancreatic cancer. The methodological quality 
of this study was very good. In a study of 127 patients, Cheon et al [27] concluded that 
elevated HbA1c levels were associated with poor survival in people with pancreatic cancer; 
however this did not reach significance.  
 
These studies suggest that increasing HbA1c is positively correlated with pancreatic cancer 
risk. However, the sample sizes are small and there are few studies for comparison. 
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Other cancers 
Four cohort studies [10, 14, 15, 17] reported data regarding HbA1c in relation to other site-
specific cancers. No significant difference in incidence of lung and prostate cancers was 
identified by Joshu [10] in people with or without diabetes. 
 
Jonasson et al [14] investigated risks for respiratory, urological, prostate and female genital 
cancers in people with type 2 diabetes. Among them, no significant differences between 
HbA1c level and hazard ratios for cancer were recognised. However, an association was 
identified by Travier [15] for respiratory cancer incidence among participants not known to 
have diabetes. A significant increase in respiratory cancer [HR 2.27, 95% CI: 1.34-3.86] was 
observed in persons with moderate HbA1c elevation (42-52mmol/mol, 6-6.9%), as compared 
to those with normal levels (<42mmol/mol, <6%). The same authors additionally revealed a 
significant increase in female genital cancer incidence [HbA1c 42-52mmol/mol/ 6-6.9%, HR 
2.84, 95% CI: 1.35-5.98; HbA1c ≥53mmol/mol/ 7%, HR 2.01, 95% CI: 0.69-5.89]. No 
significant increases in urinary or prostate cancers were observed.  
 
Hsu et al [17] found no associations between HbA1c level and lung cancer mortality in a 
cohort of people with undiagnosed diabetes or impaired fasting blood glucose.  
 
The above studies reveal that HbA1c is not associated with cancers of the prostate or 
urological tract. One large cohort study revealed that HbA1c increases are positively 
correlated to respiratory and female genital cancer risk. 
 
Discussion 
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This review is the first to systematically evaluate the evidence for an association between 
HbA1c and cancer risk/mortality. The studies included in this review report conflicting 
findings nevertheless, several conclusions can be drawn. The spread of results across the 
included studies represented a relatively large population size. Correlations generally existed 
across HbA1c ranges, as opposed to being more prevalent within diabetes versus no-diabetes. 
Therefore, glycaemia per se as opposed to a diagnosis of diabetes appears important. The 
results are consistent with studies reporting a link between the metabolic syndrome and 
increased cancer risk. 
 
The majority of studies that investigated HbA1c levels in relation to the risk of all cancers 
identified positive associations. Those with positive associations generally had larger sample 
sizes than those reporting no association. HbA1c levels <31mmol/mol (<5%) also appeared to 
be associated with increased cancer risk. However, the comparison of results between studies 
is made difficult by the heterogeneity of the cancer types that exist within each population. 
Whilst postmenopausal breast cancer or prostate cancer were the most common in the ARIC 
study [10], followed by lung and then colorectal cancer, lung and colorectal are predominant 
over prostate and breast cancer in the Japanese population. The data presented on specific 
cancer types indicates that HbA1c may have a greater association with some cancers over 
others; indeed associations may be specific to sub-types of cancer. Therefore, if any one 
cancer type is under or over represented in a population, comparing all cancer data 
interpretation is difficult. In addition, the studies that included all cancers looked at incidence 
or mortality; however the disease aetiology and progression in different cancer types varies 
markedly and will significantly impact on outcome data, depending on the dominant forms of 
cancer in a particular population. 
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The included studies that explored the relationship between HbA1c and breast cancer were all 
of good methodological quality and relatively large sample sizes. Among them, no overall 
increases in breast cancer risk were observed. The studies were carried out on varying 
populations; one study contained mainly Swedish participants and the other largely Maori 
participants. Two studies targeted women >45years while the remaining two included a wider 
range of ages. Two studies, however, did note known diabetes and HbA1c elevation to be 
weakly associated with post-menopausal breast cancer. These studies support, to an extent, 
the findings that where postmenopausal breast cancer is a predominant form of cancer in a 
population the overall correlation between HbA1c and all cancers is also positive.  
 
The majority of studies that investigated HbA1c levels in relation to colorectal cancer risk 
identified positive associations. Low HbA1c levels <31mmol/mol (<5%) were associated with 
increased colorectal cancer risk in men without diabetes and a three-fold increase in mortality 
in women in one study. The studies that failed to identify a link between HbA1c and 
colorectal cancer tended to comprise larger sample sizes than those with positive association. 
Again the population sampled may have had an impact on the results, the largest study was 
composed of 70% Maori ethnicity which may not be representative of other ethnic groups. 
Four of the eight studies were conducted on US populations, however two of these studies 
reported an association and two did not. All of the studies were nested case control studies 
with carefully selected controls; this limits the degree of selection and recall bias. Overall, we 
can conclude cases with colorectal cancer were found to have higher HbA1c levels than the 
controls; however the possibility of reverse causality cannot be completely excluded. In 
addition, iron deficiency anaemia is known to increase HbA1c level, subsequently fluctuations 
in iron status, which is common in colorectal pathology and malignancy can lead to 
deviations in HbA1c stability which has not been considered in any of the articles [29]. 
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Despite being one of the more prevalent cancers in several populations studied, there was 
little focus on lung cancer and HbA1c, in the articles identified. One study revealed risk 
increases for respiratory cancer, among people with moderate to high elevation of HbA1c. 
This study included 46,000 participants; therefore the result may be of significance and 
correlates with a study [5] that discovered that a diagnosis of diabetes may increase the risk of 
lung cancer, particularly among women. 
 
The three studies that examined HbA1c in relation to pancreatic cancer revealed similar 
findings. Two of the three studies had very similar population sizes and all had a mean age 
between 62-69 years. In each case, higher levels were associated with increased risk of 
pancreatic cancer risk and mortality, among people with and without diabetes. Poorer 
survival was noted with higher levels of HbA1c. The relationship between pancreatic cancer 
and glycaemia is complex and issues surrounding causation and effect make the results of the 
present studies difficult to interpret.  
 
Of the studies whose aims were to establish the relationship between HbA1c and gastric 
cancer, two of three failed to detect an association. The remaining study found the incidence 
of gastric cancer to be greater with higher HbA1c levels, whilst considering H. pylori as a 
confounder. However, this study was conducted in a Japanese population where gastric 
cancer is much more common. Studies that revealed a null relationship, failed to consider H. 
pylori as a potential confounder. Therefore, no firm conclusions regarding HbA1c and 
gastrointestinal cancer risk can be made. 
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All but one of the studies, reporting data for HbA1c in relation to other site-specific cancers, 
determined no differences in risk for respiratory, urological, female genital or prostate 
cancers. 
 
Given the results of this review, the monitoring and optimisation of glycaemia, using HbA1c 
as a measure of hyperglycaemia, could be considered as a modifiable risk factor for certain 
cancers, along with well-established risk factors such as smoking and alcohol. With further 
research, HbA1c could aid in informing prognosis for certain cancers as extremes of HbA1c 
level are correlated with increased cancer mortality. The European Prospective Investigation 
into Cancer and Nutrition (EPIC) study is ongoing and further research generated from this 
large cohort study may contribute to our knowledge of HbA1c and cancer risk. 
 
This systematic review has some limitations. One is the inability to perform a meta-analysis 
due to heterogeneity of the results and study design. Within the studies, little differentiation 
was made between type 1 and type 2 diabetes yet the two disease progressions may 
contribute to different risk profiles for cancer which was not accounted for. Furthermore, the 
role of anti-diabetic treatment on cancer risk has not been accounted for in all of the studies. 
Most studies only had one HbA1c measurement per case, this means temporal relationships 
cannot be compared between studies. Finally, reverse causality cannot be excluded in any of 
the studies. 
 
Since the publication of most of the included studies, standards for HbA1c measurement have 
improved, further studies should ensure that all HbA1c measurements are performed in 
alignment with the IFCC and clear quality data should be provided in the reports [30]. 
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Conclusions  
In conclusion, there is evidence that HbA1c may predict overall and certain site specific 
cancer risk/mortality in people with or without diabetes. Further studies looking at specific 
cancers, where a positive correlation has been shown, are warranted. Whilst data is currently 
mixed, understanding the role of HbA1c and glycaemia in the aetiology of specific cancers 
may help to identify where HbA1c can give additional information to support either 
identification of people at risk of cancers or give some insight into the potential progression 
of the disease.  
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Table 1. Summary of all study characteristics 
Author/Year Study HbA1c stratification N (males) Inclusion Criteria Diabetes status Cancer 
type 
Follow up 
duration 
Adjusting factors 
Nakanishi et 
al  2005 
Cohort; from Adult 
Health Study (1986-
1994) 
Known diabetes and remaining 
into 4 groups of baseline data 
[<5.5%, ≥5.5 - <6.0%, ≥6.0 - 
<6.5% and ≥6.5%] 
3,710 
(1,142) 
Male and female; A-bomb survivors and 
controls; Nagasaki Adult Health Study 
population excluded 
 
Mixed  
 
Overall 8.83 (mean) Age; sex; A-bomb kerma dose; BMI; 
systolic BP; total cholesterol;  smoking; 
alcohol 
Parekh et al 
2010 
Observational; from 
NHANES III 
Per 2% increments 15,594 
(7,594) 
Male and female; 20-89 years; subjects 
meeting at least 3 of the 5 criteria for the 
IRSa; pregnant women excluded 
Mixed  Overall 8.5 (mean) 
8.55 
(median) 
Age; race; sex; smoking; physical activity; 
BMI 
Saydah et al  
2009 
Cohort; from 
NHANES III 
 
4 groups of baseline data [<6.0, 
6.0- <7.0, 7.0- <8.0 and ≥8.0%] 
 
19,025 
(8,517) 
Male and female;≥20 years; participants 
with complete data for all variables 
included in the analysis 
 
Mixed Overall 6-12 
(range) 
Age; sex; race/ethnicity; education level; 
smoking; BMI; systolic BP; HDL 
cholesterol 
Joshu et al  
2012 
Cohort; from ARIC 
study (1990-92) 
 
According to diabetic status 
(diabetic [≤7 and >7%], and non-
diabetic [<5.0, 5.0-5.6 and 
≥5.7%] ≥5.7% further classified 
into ≥5.7-6.4 and ≥6.5%) 
12,792 
(5,790) 
Male and female; 45-64 years; no prior 
cancer diagnosis (except non-melanoma 
skin) by second examination visit within 
ARIC study 
Mixed   Overall/ 
specific 
sites 
15 (median) Age; sex; race/ethnicity; education level; 
smoking; BMI; waist circumference; PM 
hormone use 
Silbernagel et 
al   
2011 
Cohort; from the 
LURIC health study 
6 groups of baseline data [<5.0, 
5.0-5.4, 5.5-5.9, 6.0-6.4, 6.5-7.4 
and ≥7.5%] 
2,696 
(1,897) 
Male and female; German ancestry; the 
availability of a coronary angiogram; no 
acute illnesses/chronic non-cardiac 
diseases or malignancies within past 5 
years 
No diabetes Overall 7.54 (mean) Sex; age; BMI; hypertension; smoking; 
GFR; triglycerides; LDL/HDL cholesterol; 
fasting glucose 
Hsu et al   
2013 
Cohort; from 
NHANES III  
According to baseline median 
and [interquartile range] Male = 
5.51% [5.16-5.98%] Female = 
5.56% [5.25-5.94%] 
2,509 
(1,348) 
Male and female; ≥40 years; impaired 
fasting blood glucose/undiagnosed 
diabetes; no previous history of 
malignancy 
No diabetes Overall/ 
lung 
11.17 
(mean)    
0-18.17 
(range) 
Age; sex; BMI; race/ethnicity; smoking 
Travier et al  
2007 
Cohort; from a 
hepatitis B screening 
programme (1999-
2001) 
3 groups of baseline data [6.0, 
6.0-6.9, and ≥7.0%] 
46,575 
(20,761) 
Male and female; ≥18 years; no 
participants who had a cancer registered or 
a diabetes diagnosis before their HbA1c 
test 
No diabetes Overall/ 
specific 
sites 
4.4 
(median) 
Sex; age; ethnicity; smoking; 
Jonasson et al  
2012 
Cohort; from 
Swedish National 
Diabetes Register 
from 1997-99 
According to cohort median 
[≤58 mmol/mol (7.5%), >58 
mmol/mol] – baseline and 
updated mean 
25,476 
(14,259) 
Male and female; 25-90 years; no cancer 
diagnosis or death before the start of 
follow-up 
Type 2 diabetes Overall/ 
specific 
sites 
11-13 
(range) 
Age; sex; diabetes duration; BMI; smoking; 
insulin treatment 
Cheon et al  
2014 
Cohort; admitted to 
Konkuk University 
Medical Center from 
2005 to 2011 
<7.0%, ≥7.0%. 127 (60) Male and female; 43-90 years; stage 3 or 
above pancreatic cancer 
Mixed  Pancreatic 7 (mean) Age; sex; TNM; BMI; alcohol; smoking; 
chemotherapy;Ca19-9 
Grote et al  
2011 
Nested case-control; 
conducted within 
EPIC 
Quintiles of baseline data [4.8-
5.4, 5.5-5.7, 5.8-5.9, 6.0-6.4 and 
6.5-11.0%] 
Case/contro
l  
466 (225) 
Male and female; 30-76 years; no 
occurrence of other malignant tumours 
preceding pancreatic cancer diagnosis 
Mixed  Pancreatic  5.3 (mean) 
0-13 
(range) 
Age; sex; smoking; BMI; diabetes status; 
fasting time 
Wolphin et al  Nested case-control; quintile 1 median [4.77%] Case 449 Male and female;≥30 years; pancreatic No diabetes Pancreatic 10-26 Sex; age; BMI; smoking; race; fasting status; 
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2013 from 5 prospective 
studiesc 
 
quintile 2 median [4.95%] 
quintile 3 median [5.09%] 
quintile 4 median [5.24%] 
quintile 5 median [5.50%] 
(128) 
Control 
982 (288) 
adenocarcinoma cases diagnosed through 
2008 with available plasma and no prior 
cancer (except non-melanoma skin); 
controls without cancer at case patient’s 
diagnosis 
(range) fasting time 
Ikeda et al  
2009 
Cohort; from 1988 
screening survey in 
Hisayama, Japan 
4 groups of baseline data with 
1% intervals [≤4.9, 5.0-5.9, 6.0-
6.9 and ≥7.0%] 
2,603 
(1,070) 
Male and female; ≥40 years; no prior 
history of gastrectomy or gastric cancer 
Mixed Gastric 14 (mean) Age; sex; Helicobacter pylori seropositivity; 
history of peptic ulcer disease; BMI; total 
serum cholesterol; alcohol; smoking 
Hsu et al   
2012 
Cohort; from a 
voluntary health 
check-up programme 
According to status of colorectal 
neoplasia (any/high-risk/none) 
2,776 
(1,506) 
Male and female; 18-86 years; no 
participants whose colonoscopy failed 
cecal intubation 
Mixed Colorectal 2 (mean) Age; sex; BMI; smoking; alcohol; diabetes 
status; FPG; physical activity; LDL/HDL; 
family history 
Khaw et al  
2004 
Cohort; from EPIC-
Norfolk study 
Known diabetes, likely 
undiagnosed diabetes [≥7%] and 
3 groups of baseline with 1% 
intervals [<5.0, 5.0-5.9 and 6.0-
6.9%] 
9,605 
(4,445) 
Male and female; 45-79 years; available 
HbA1c measurement; no prevalent cancer 
at baseline survey 
Mixed Colorectal 6 (mean) Age; sex; BMI; smoking 
Rinaldi et al  
2008 
Nested case-control; 
conducted within 
EPIC 
Quintiles of baseline data [≤5.4, 
5.4-5.6, 5.6-5.8, 5.8-6.1 and 
>6.1%] 
Colon 
case/contro
l 644 (342) 
Rectum 
case/contro
l 382 (219) 
Male and female; 35-69 years; cases who 
developed colon/rectum cancers after 
recruitment and before end of study; anal 
cancer excluded; controls free of cancer 
(except non-melanoma skin) at time of 
diagnosis of the index case 
Mixed  Colorectal 3-10 
(range) 
Age; sex; menopausal status; waist to hip 
ratio; alcohol; diabetes status; fasting status; 
follow-up time 
Platz et al  
1999 
Nested case-
control; conducted 
within the Nurses’ 
Health Study 
Tertiles of baseline data 
(tertile 1 median [5.2%], 
tertile 2 median [5.5%], 
tertile 3 median [5.8%] 
Cancer 
case/contr
ol 79 (0) / 
156 (0) 
DA 
case/contr
ol 201 (0) 
Female only; 30-55 years; controls 
who supplied blood sample in 1989-
90 and were free of diagnosed cancer 
(except non-melanoma skin); cases 
who received colorectal cancer 
diagnosis after date of blood return 
and through 31 May 1994 
No diabetes Colorectal 8 (mean) Age; weight; BMI; physical activity; 
smoking; alcohol; red meat intake; folic 
acid; methionine; aspirin use; PM 
hormone use; fasting status 
Saydah et al  
2003 
Nested case 
control; conducted 
within CLUE II 
cohort 
Quartiles of baseline data 
(quartile cut points = 5.38, 
5.54 and 5.78%) 
Case 173 
(NA) 
Control 
346 (NA) 
Male and female; cases whose 
colorectal cancers diagnosed after 
date of blood draw, through 
December 2000, and did not have a 
prior cancer diagnosis (except non-
melanoma skin). Controls who did 
not have cancer diagnosis through 
December 2000 
No diabetes Colorectal 11 (mean) Age; sex; race; date of blood draw; time 
since last meal; other circulating 
markers included in studyb 
Lin et al   
2005 
Cohort; from the 
Women’s Health 
Study 
Quartiles of baseline data 
[2.3-4.8, >4.8-5.0, >5.0-5.2 
and ≥5.2%] 
27,110 (0) Female only; ≥45 years; free of 
cancer and cardiovascular disease at 
time of enrolment in 1993 
No diabetes Colorectal  10 (mean) Age; RTA; BMI; family history; history 
of colon polyps; physical activity; 
smoking; red meat intake; alcohol; 
multivitamin use; menopausal status; 
PM hormone use 
Lin et al   Cohort; from the Quintiles of baseline data 27,110 (0) Female only; ≥45 years; free of No diabetes Breast 10 (mean) Age; RTA; BMI; family history; history 
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2006 Women’s Health 
Study 
[≤4.80, >4.80-4.94, >4.94-
5.07, >5.07-5.25 and 
>5.25%], 5 groups of 
clinically-relevant cut-offs 
[<5.0, 5.0-<5.5, 5.5-<6.0, 
6.0-<6.5 and ≥6.5%] 
cancer and cardiovascular disease at 
time of enrolment in 1993 
of benign breast disease; physical 
activity; alcohol; age at menarche/first 
birth; menopausal status; PM hormone 
use 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: BMI = body mass index, BP = blood pressure, FPG = fasting plasma glucose, GFR = glomerular filtration rate, HDL = high-density lipoprotein, IRS = insulin resistance syndrome, LDL = low-density 
lipoprotein, NA = not available, PM = post-menopausal, RTA = random treatment assignment. b Other studied circulating markers include: plasma insulin, the ratio of total cholesterol:HDL cholesterol, triglycerides and 
IGFBP-1. 
a Five criteria for the insulin resistance syndrome: (1) insulin resistance [fasting glucose ≥6.1 mmol/l], (2) hypertension [systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥ 85 mmHg], (3) hypertriglyceridemia 
[triglycerides ≥1.7 mmol/l], (4) low high-density cholesterol levels [<1.0mmol/l in men or <1.3mmol/l in women], and (5) abdominal obesity [waist circumference >102 cm in men or >88 cm in women].  
b Other studied circulating markers include: plasma insulin, the ratio of total cholesterol:HDL cholesterol, triglycerides and IGFBP-1. 
c Five prospective studies = Health Professionals Follow-up Study (HPFS), Nurses’ Health Study (NHS), Physicians’ Health Study (PHS), Women’s Health Initiative-Observational Study (WHI-OS) and Women’s Health Study 
(WHS). 
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Table 2. A summary of the results of studies that investigated HbA1c in relation to all cancers. 
  Hazard Ratio (95% Confidence Interval) for HbA1c Categorisations 
Study Subject 
Groups 
≤5.0% 5.0-5.6% ≤5.5% 5.5-5.9% ≥5.7% 6.0-6.4% ≥6.5% ≤58 mmol/ 
mol 
>58 mmol/mol Diabetes Overall 
Hsu et al. 
(2013) 
 
Male 
 
Female 
 
- 
 
- 
- 
 
- 
- 
 
- 
- 
 
- 
- 
 
- 
- 
 
- 
- 
 
- 
- 
 
- 
- 
 
- 
- 
 
- 
1.24(0.90-
1.70) 
0.97(0.57-
1.65) 
 
Jonasson et al. 
(2012) 
 
All - - - - - - - 1 1.02 (0.95-1.09) 
 
- - 
Joshu et al. 
(2012) 
 
 
 
Male 
incidence* 
 
*Minus 
prostate 
 
Male 
mortality* 
 
*Minus 
prostate 
  
Female 
incidence 
 
Female 
mortality 
1.04 (0.85-
1.27) 
 
1.16 (0.90-
1.50) 
 
0.97 (0.67-
1.40) 
 
0.89 (0.60-
1.32) 
 
1.27 (1.02-
1.58) 
 
1.82 (1.25-
2.64) 
1 
 
 
1 
 
 
1 
 
 
1 
 
 
1 
 
 
1 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
1.08(0.95-
1.22) 
 
1.11(0.95-
1.31) 
 
1.08(0.87-
1.33) 
 
1.01(0.80-
1.26) 
 
1.24(1.07-
1.44) 
 
1.58(1.23-
2.05) 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
0.85(0.69-1.05) 
 
0.96(0.74-1.24) 
 
0.92(0.66-1.30) 
 
0.92(0.65-1.30) 
 
1.30(1.06-1.60) 
 
1.96(1.40-2.76) 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
 
Nakanishi et al. 
(2005) 
 
All 
 
 
 
- 
 
- 
 
 
 
1 
 
1.10(0.77-
1.56) 
 
- 
 
1.30(0.85-
2.00) 
 
1.70(1.02-
2.82) 
 
- 
 
- 
 
1.82(1.20-2.76) 
 
- 
 
  Hazard Ratio (95% Confidence Interval) for HbA1c Categorisations 
Study Subject 
Groups 
<5% 5.0-5.4% 5.5-5.9% <6% 6.0-6.4% 6.0-6.9 6.5-7.4 7.0-7.9% ≥7.0% ≥7.5% ≥8.0% Per 2% 
Increment 
Parekh et al. 
(2010) 
All 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
1.22(0.96-
1.55) 
 
Saydah et al. 
(2009) 
 
 
 
All 
 
 
Diabetes 
 
 
No diabetes 
 
- 
 
 
- 
 
 
- 
 
- 
 
 
- 
 
 
- 
 
- 
 
 
- 
 
 
- 
 
1 
 
 
1 
 
 
1 
 
- 
 
 
- 
 
 
- 
 
0.73 (0.5-1.1) 
 
0.20(0.05-
0.90) 
 
0.8 (0.6-1.2) 
 
- 
 
 
- 
 
 
- 
 
0.93 (0.4-
2.2) 
 
0.43(0.08-
2.28) 
 
0.6 (0.1-
 
- 
 
 
- 
 
 
- 
 
- 
 
 
- 
 
 
- 
 
2.64 (1.2-6.0) 
 
1.04(0.25-4.24) 
 
0.8 (0.3-2.5) 
 
- 
 
 
- 
 
 
- 
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  2.3) 
 
Silbernagel et 
al. (2011) 
 
 
All 
 
2.03 (0.76-
5.40) 
 
0.82 
(0.39-
1.72) 
 
1 
 
- 
 
0.93(0.50-
1.74) 
 
- 
 
1.85 (0.98-
3.48) 
 
- 
 
- 
 
1.67 
(0.46-
6.11) 
 
- 
 
- 
Travier et al. 
(2007) 
All - - - - - 1.40(1.11-
1.76) 
 
- - 1.09 
(0.80-
1.48) 
 
- - - 
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Appendix 1. Embase/Medline search strategy  
1. neoplasm/ 
2. "neoplasm*".ti. 
3. "cancer*".ti. 
4. "tumo?r*".ti. 
5. "malignan*".ti. 
6. "carcinogen*".ti. 
7. 1 or 2 or 3 or 4 or 5 or 6 
8. diabetes mellitus/ 
9. "diabet*".ti,ab. 
10. "nondiabet*".ti,ab. 
11. insulin blood level/ or insulin resistance/ or human insulin/ or insulin dependence/ or 
insulin sensitivity/ or insulin deficiency/ or non insulin dependent diabetes mellitus/ or insulin 
release/ or insulin dependent diabetes mellitus/ or insulin metabolism/ or insulin/ 
12. "insulin*".ti,ab. 
13. "insulin resistan*".ti,ab. 
14. "insulin insensitiv*".ti,ab. 
15. "insulin dependen*".ti,ab. 
16. "noninsulin dependen*".ti,ab. 
17. "non-insulin dependen*".ti,ab. 
18. "hyperinsulin?emi*".ti,ab. 
19. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 
20. blood glucose monitoring/ or glucose intolerance/ or glucose/ or glucose metabolism/ or 
glucose blood level/ or glucose tolerance/ 
21. "glucose".ti,ab. 
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22. "glyc?emi*".ti,ab. 
23. "hyperglyc?emi*".ti,ab. 
24. 20 or 21 or 22 or 23 
25. glycosylated hemoglobin/ or diabetes mellitus/ 
26. "a1c".ti. 
27. "hba1c".ti. 
28. "glyc* h?emoglobin".ti. 
29. "glycoh?emoglobin".ti. 
30. 25 or 26 or 27 or 28 or 29 
31. risk/ or cancer risk/ 
32. "risk*".ti.  
33. "predict*".ti. 
34. "associat*".ti. 
35. "factor*".ti. 
36. "relationship*".ti. 
37. "predispos*".ti. 
38. "mortalit*".ti. 
39. 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 
40. 7 and 19 and 24 and 30 and 39 
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